SITC 2022 Posters

Explore How Spatial Signatures are Changing Immuno-oncology!

The emergence of new immunotherapies as the first line of treatment for cancer, necessitates the development of clinically useful biomarkers to select responders that will be critical for the advancement of such treatments. Join us to learn about advancements in developing spatial signatures, predictive biomarkers based on spatial relationships and protein co-expression on specific cellular subsets that are assessed within the context of the tumor microenvironment (TME). Visit our booth and view our posters to find out more about Akoya’s new multiplex panels that provides you the flexibility to keep pace with the ever-changing combination therapy landscape.

You Won’t Want to Miss this Workshop!

Supercharging Spatial Signature Development: Predictive Biomarkers for the Ever-Changing Immunotherapy Landscape
Akoya will be launching new Spatial Signature Panels at SITC. Join us on Thursday evening at our dinner symposium for the big reveal! Learn from our panel of speakers about our new multiplex panels based on novel protein chemistry that can accelerate the development of spatial signatures. Don’t forget to pre-register on this page to reserve your seat!
Date: November 10th, 2022
Time: 7:30 pm – 9:30 pm EST
Location: BCEC 156 – Boston Convention Center
Speakers:

Oliver Braubach, PhD

Director of Applications,
Akoya Biosciences

Patrick Savickas

Lead Scientist,
HistoWiz

Arutha Kulasinghe, PhD

NHMRC Research Fellow and Group Leader,
University of Queensland

Posters to Check Out

Hall C: Friday, Nov. 11 from 11:55–1:25 pm and 7–8:30 pm

Authors: Rachel Schaefer1,  Jacob Circelli1, Oscar Perez1, Linying Liu1, Michael McLane1, Yi Zheng1
1Akoya Biosciences, Inc. 1080 O'Brien Dr Suite A, Menlo Park, CA 94025 USA

Authors: Ning Ma1, Aditya Pratapa1, James Monkman2, Ken O’Byrne3, Oliver Braubach1, Arutha Kulasinghe2
1Akoya Biosciences, Inc. 1080 O'Brien Dr Suite A, Menlo Park, CA 94025 USA
2University of Queensland, Brisbane, QLD, Australia
3Princess Alexandra Hospital, Brisbane, QLD, Australia

Authors: Dmytro Klymyshyn1, Niyati Jhaveri1, Oliver Braubach1, Subham Basu3, Michael Prater3, Keith L. Black2 & Tao Sun2
1Akoya Biosciences, Inc. 1080 O'Brien Dr Suite A, Menlo Park, CA 94025 USA
2Department of Neurosurgery, Cedars-Sinai Medical Center. 8700 Beverly Blvd, Los Angeles, CA 90048
3Abcam, Biomedical Campus, Discovery Drive, Trumpington, Cambridge CB2 0AX, United Kingdom

Hall C: Thursday, Nov. 10 from 11:40–1:10 pm and 7:30–9 pm

Authors: Nicole Couper1, Bethany Remeniuk2, Karen McClymont1, Bei Hopkins2, Natalie Monteiro2, Lorcan Sherry1, Darren Locke2
1OracleBio Ltd, Glasgow, Scotland, UK
2Akoya Biosciences, Inc, Marlborough, Massachusetts, USA

Authors: Arutha Kulasinghe2, Niyati Jahveri3, Dmytro Klymyshyn3, Bassem Ben Cheikh3, Rahul Ladwa1, Howard Liu1, Caroline Cooper1, Gabrielle Belz2, Subham Basu4, Michael Prater4, Oliver Braubach2, Sandro Porceddu1
1Princess Alexandra Hospital, Brisbane, QLD, Australia
2University of Queensland, Brisbane, QLD, Australia
3Akoya Biosciences, Inc. 1080 O'Brien Dr Suite A, Menlo Park, CA 94025 USA
4Abcam, Biomedical Campus, Discovery Drive, Trumpington, Cambridge CB2 0AX, United Kingdom

Authors: Bethany Remeniuk1, Bei Hopkins1, Natalie Monteiro1, Darren Locke1
1Akoya Biosciences, Inc. 1080 O'Brien Dr Suite A, Menlo Park, CA 94025 USA